Bioventus upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Bioventus (BVS) to Neutral from Underweight with a price target of $13, up from $12. The firm cites better visibility into the company’s growth and several quarters of improved execution for the upgrade. 2024 marked a return to stability for Bioventus, with hyaluronic acid headwinds now lapped and “fully in the rearview and pockets of strength in areas like Ultrasonics,” the analyst tells investors in a research note. As such, JPMorgan feels incrementally more positive about Bioventus into 2025.